

# Immunomodulatory effects of a probiotic drink containing *Lactobacillus casei* Shirota in healthy older volunteers

Dong, H., Rowland, I., Thomas, L. V. & Yaqoob, P.

Author post-print (accepted) deposited by Coventry University's Repository

**Original citation & hyperlink:**

Dong, H, Rowland, I, Thomas, LV & Yaqoob, P 2013, 'Immunomodulatory effects of a probiotic drink containing *Lactobacillus casei* Shirota in healthy older volunteers' *European Journal of Nutrition* , vol. 52, no. 8, pp. 1853–1863.

<https://dx.doi.org/10.1007/s00394-012-0487-1>

DOI 10.1007/s00394-012-0487-1

ISSN 1436-6207

ESSN 1436-6215

Publisher: Springer

*The final publication is available at Springer via <http://dx.doi.org/10.1007/s00394-012-0487-1>*

Copyright © and Moral Rights are retained by the author(s) and/ or other copyright owners. A copy can be downloaded for personal non-commercial research or study, without prior permission or charge. This item cannot be reproduced or quoted extensively from without first obtaining permission in writing from the copyright holder(s). The content must not be changed in any way or sold commercially in any format or medium without the formal permission of the copyright holders.

This document is the author's post-print version, incorporating any revisions agreed during the peer-review process. Some differences between the published version and this version may remain and you are advised to consult the published version if you wish to cite from it.

**Immunomodulatory effects of a probiotic drink containing *Lactobacillus casei* Shirota in healthy older volunteers**

Honglin Dong<sup>1</sup>, Ian Rowland<sup>1</sup>, Linda V. Thomas<sup>2</sup> and Parveen Yaqoob<sup>1</sup>

<sup>1</sup>Department of Food and Nutritional Sciences, The University of Reading, Whiteknights PO Box 226, Reading RG6 6AP, UK

<sup>2</sup>Yakult UK Ltd, Artemis, Odyssey Business Park, West End Rd, Ruislip HA4 6QE, UK

**Correspondence:** Professor Parveen Yaqoob, Food and Nutritional Sciences, University of Reading, Whiteknights PO Box 226, Reading RG6 6AP, United Kingdom.

**E-mail:** p.yaqoob@reading.ac.uk.

**Telephone:** +44(0)1183788720

**Fax:** +44(0)118 378 7708

1 **Abstract**

2 **Purpose:** There is growing evidence that probiotics confer health benefits to the host by modulating immune  
3 function, especially in older people, where immunosenescence is a feature even of healthy ageing. The aim of  
4 this study was to investigate the effect of a probiotic drink containing *Lactobacillus casei* Shirota (LcS) on  
5 immune function in a healthy non-immunocompromised older population. **Methods:** Thirty healthy old  
6 volunteers were recruited into a randomized placebo-controlled, single-blind crossover study. The volunteers  
7 were supplemented with the probiotic drink containing  $1.3 \times 10^{10}$  CFU LcS or skimmed milk per day for 4  
8 weeks, followed by 4 weeks of washout and were crossed over to the other treatment. Peripheral blood and  
9 saliva samples were collected at baseline and end of each treatment. **Results:** Probiotic consumption was  
10 associated with a significant increase in natural killer (NK) cell activity relative to baseline and a significant  
11 decrease in MFI of CD25 expression in the resting T cells compared with placebo. Additionally there was a  
12 trend towards an increased ratio of IL-10 to IL-12 relative to baseline after LcS intake. **Conclusions:**  
13 Consumption of a probiotic drink containing *L. casei* Shirota improved NK cell activity and tended to  
14 produce a more anti-inflammatory cytokine profile in an older population.

15 **Keywords:**

16 Cytokine; immune function; *Lactobacillus casei* Shirota; lymphocyte; probiotic

17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27

## 1   **Introduction**

2       The growth of the older population in most developed countries is set to continue to rise. Health issues  
3   faced by older people include a greater susceptibility to infection. It is well known that immune function  
4   becomes compromised with age, an effect known as immunosenescence [1]. Decreases in the numbers of T  
5   cells in peripheral blood, decreased capacity of T cells to proliferate and secrete cytokines, poor contribution  
6   to effective delayed-type hypersensitivity responses *in vivo*, a decline in innate immunity, including  
7   phagocytic and NK cell activity [2], and a decrease in specific antibody responses have all been reported in  
8   older people [3]. A poorly functioning immune system compromises the ability to respond to infections and  
9   to develop increased protection after vaccination, which contributes to a higher mortality rate in older people.

10       The human gastrointestinal tract supports a rich and complex microbiota, whose composition and activity  
11   play very important roles in nutrition, immunology and specific disease processes. It is reported that in older  
12   people, the numbers and species diversity of many beneficial or protective anaerobes, such as lactobacillus  
13   and bifidobacteria, are reduced [4]. This is particularly the case in antibiotic-treated elderly individuals, who  
14   also experience an increase in bacteria groups believed to be detrimental to health, such as facultative  
15   anaerobes, clostridia, enterobacteria, eubacteria and proteolytic bacteria [5]. Knowledge of the composition  
16   of the elderly gut microbiota leads to an attractive means of dietary intervention by probiotic supplementation  
17   with immune-stimulating strains of lactic acid bacteria. Some human studies have reported that probiotic  
18   strains boost natural killer (NK) cell activity [6] and phagocytic activity [6-7] in healthy volunteers and have  
19   beneficial effects in inflammatory and atopic diseases, possibly by modulating the production of pro- and  
20   anti-inflammatory cytokines [8]. There are very limited data, however, regarding the effect of probiotics on  
21   acquired immunity, in particular in older people.

22       Yakult is a fermented milk drink containing the probiotic *Lactobacillus casei* Shirota (LcS), which has  
23   been shown to survive digestion in the gut and reach the large intestine in a viable state [9]. Evidence from  
24   human studies suggests that LcS increases the number of beneficial intestinal bacteria, achieving a balance  
25   between beneficial and harmful intestinal bacteria [10], improves constipation [11], modulates immune  
26   function [12], alleviates the severity of symptoms in allergic rhinitis [13] and reduces risk of infection [14].  
27   The effects of probiotics on immune function extend to a wide range of parameters, with NK activity being  
28   one of the most commonly modulated. **Each of the aspects of immunity evaluated in this study is subject to  
29   modulation by ageing; the hypothesis of this study was that LcS would at least partially reverse some of the  
30   decline in immune parameters caused by ageing. Of course, we cannot be sure that the elderly subjects who  
31   took part in this study were immunocompromised. However, immunosenescence is universally associated**

1 with ageing, and is observed even in healthy ageing. The purpose of this study was not to select an  
2 immunocompromised group of subjects, but an older group that was expected to have some degree of  
3 immunosenescence. In this study, we assessed a wide range of immune parameters, since there are limitations  
4 associated with the evaluation and interpretation of single immune biomarkers.

## 5 **Materials and methods**

### 6 **Subjects**

7 Thirty healthy volunteers, 18 female and 12 male, 55-74 years old, were recruited for this study. The  
8 sample size was calculated by G\* power software v 3.0.10 (Mahhneim, Germany), based on improved NK  
9 cell activity by *L. paracasei* (NCC 2461) supplement [2] with the effect size of 0.9, a two-sided significance  
10 level of 5 % and a power of 95 %. The inclusion criteria included 55-80 years old, body mass index (BMI)  
11 19-30 Kg/m<sup>2</sup>, and good general health. The exclusion criteria were anemia, milk allergy and lactose  
12 intolerance, any ongoing inflammatory or infectious disease, any autoimmune disease, malignancy, cirrhosis,  
13 use of anti-inflammatory or immunomodulating medication (including oral prednisone and other steroids)  
14 currently or within four weeks; use of antibiotics within 3 months, vaccination within six months and  
15 alcoholism and drug misuse. All volunteers signed an informed consent form, and agreed to conform to the  
16 trial guidelines and provide notification of any non-compliance.

### 17 **Study design**

18 The study protocol was approved by the Research Ethics Committee at the University of Reading  
19 (Research Ethics Committee Project No. 09/34) and was performed in accordance with the ethical standards  
20 laid down in the 1964 Declaration of Helsinki. All the volunteers gave their informed consent prior to their  
21 inclusion in the study. The study was designed as a randomized placebo-controlled single-blind crossover  
22 study with a two week run-in period prior to the beginning of the study, when volunteers were required to  
23 refrain from any probiotic or prebiotic containing food or drinks and record a 4-day food diary, including one  
24 weekend day, to assess habitual diet. The volunteers were randomized by an Excel-based covariate adaptive  
25 randomization program [15] to enter two intervention arms: probiotic (10 female, 6 male) or placebo (8  
26 female, 6 male) stratified by age, gender and BMI. The placebo consisted of commercially available UHT  
27 skimmed milk in sterile containers labelled 'test milk', since its nutrient content very closely matches that of  
28 Yakult Light, but the subjects were unaware of the identity of the test milk. The volunteers were informed  
29 that the study was a comparison of the effects of the "test milk" with Yakult on immune function. Therefore,  
30 the study was single-blind as the subjects were unaware that the "test milk" was the placebo, or that only one

1 of the products contained a probiotic. The subjects consumed 2×65mL bottles of Yakult Light (commercially  
2 available) containing  $6.5 \times 10^9$  CFU/bottle during the probiotic intervention period, and skimmed milk (130  
3 mL per day) during the placebo intervention period for 4 weeks on each arm, with a 4-week washout period.  
4 At baseline and at the end of each intervention period, overnight fasting venous blood samples were collected  
5 for immunological and biochemical analysis and saliva was collected for sIgA measurement.

#### 6 **Preparation of PBMC**

7 Fasted blood samples were taken from volunteers in sodium heparin vacutainer tubes (Greiner Bio-One  
8 Ltd, Gloucestershire, UK). Blood was layered over an equal volume of Lympholyte (Cedarlane Laboratories  
9 Limited, Tyne & Wear, UK) and centrifuged at  $930 \times g$  for 15 min at room temperature. The plasma was  
10 removed into a sterile tube for later use. Cells were harvested from the interface, washed once, resuspended  
11 in RPMI 1640 medium (Autogen Bioclear, Wiltshire, UK) containing 0.75 mM glutamine (Autogen  
12 Bioclear, Wiltshire, UK), and the above steps were then repeated to achieve a lower degree of erythrocyte  
13 contamination. The pellet was finally resuspended in RPMI and the cell number was adjusted to the required  
14 concentration.

#### 15 **Preparation of other samples**

16 Blood was collected by serum separator vacutainer tube (BD Biosciences, Oxford, UK) and centrifuged at  
17  $2095 \times g$  for 10 min. Aliquots of serum were stored at  $-20^\circ\text{C}$  for later analysis of C5a, cholesterol,  
18 triacylglycerol, glucose and C-reactive protein (CRP). Saliva samples were collected and centrifuged at  
19  $13000 \times g$  for 10 min. Aliquots of supernatant were stored at  $-20^\circ\text{C}$  for later analysis of sIgA.

#### 20 **Blood lipids, glucose and immune/inflammatory markers**

21 The concentrations of serum cholesterol, triacylglycerol, glucose and C-reactive protein (CRP) were  
22 evaluated by iLab 600 (all kits and equipment from Instrumentation Laboratory, Warrington, UK). C5a in  
23 serum and sIgA in saliva samples were detected by commercial ELISA kits (C5a, BD Biosciences, Oxford,  
24 UK; sIgA, Oxford Biosystems, Oxford, UK), following the manufacturers' instructions.

#### 25 **White blood cell (WBC) count**

26 Twenty microliters of whole blood were diluted with 10 mL isoton (Beckman Coulter, High Wycombe,  
27 UK). Zapoglobin (Beckman Coulter, High Wycombe, UK) was added for 5 minutes, and WBCs were  
28 counted in the coulter (Coulter Z1 single 1.2.00, Beckman Coulter, High Wycombe, UK).

#### 29 **Phagocytic activity of leucocytes**

30 Phagocytic activity of granulocytes and monocytes was determined using a commercial kit (ORPEGEN  
31 Pharma, Heidelberg, Germany). Heparinized blood was incubated with fluorescein-labeled opsonized

1 *Escherichia coli* at 37°C for 10 min. The reaction was stopped by addition of a quenching solution. After two  
2 wash steps, lysing solution was added and incubated for 20 min at room temperature, followed by another  
3 two wash steps before addition of DNA stain, propidium iodide (PI) (Sigma, Dorset, UK). The percentage of  
4 granulocytes or monocytes engaged in phagocytosis of *E. coli* and the mean fluorescence intensity (MFI)  
5 were detected by flow cytometry. Data was analyzed using FlowJo 7.6 software.

#### 6 **Ex vivo culture conditions**

7 PBMCs, adjusted to  $2 \times 10^6$  cells/mL, were incubated in 24-well plates in the absence or presence of 1  
8  $\mu\text{g/mL}$  lipopolysaccharide (LPS) (L4516, Sigma, Dorset, UK) or 2.5  $\mu\text{g/mL}$  concanavalin A (ConA) (Sigma,  
9 Dorset, UK) and 2.5 % autologous plasma for 24h at 37 °C in an air/CO<sub>2</sub> (19:1) atmosphere. At the end of the  
10 incubation, Con A-stimulated cells were stained for activation markers and supernatants from LPS-stimulated  
11 cells were collected and stored at -20°C for later analysis of cytokine production.

#### 12 **NK cell activity**

13 Freshly prepared PBMCs were adjusted to a concentration of  $5 \times 10^6$  cells/mL. Viable target cells (K562  
14 cell line) were enumerated by microscopy of trypan blue-stained cell preparations and  $5 \times 10^6$  cells were  
15 collected and washed twice with PBS before incubation with carboxyfluorescein diacetate succinimidyl ester  
16 (CFDA-SE) (1  $\mu\text{g/mL}$ ) (Sigma, Dorset, UK) for 45 min at 37 °C in an air/CO<sub>2</sub> (19:1) atmosphere. After  
17 incubation, the target cells were washed twice and resuspended in 1 mL of complete medium composed of  
18 RPMI 1640 medium, 0.75 mM glutamine and 10 % newborn calf serum (Sigma, Dorset, UK). PBMCs were  
19 incubated with CFDA-SE labeled target cells for 2 h at 37 °C in an air/CO<sub>2</sub> (19:1) atmosphere at effector to  
20 target cell ratios of 100:1, 50:1, 25: 1 and 12.5: 1. Twenty microliters of PI at 1 mg/mL were added to the  
21 samples prior to analysis by flow cytometry. The results were expressed as the percent lysis of the target  
22 cells. FlowJo 7.6 software (Tree Star, Inc., Ashland, USA) was used to perform the data analysis.

#### 23 **Lymphocyte phenotype and activation analysis**

24 Cells were stained with appropriate combinations of fluorescently-labeled mouse anti-human monoclonal  
25 antibodies for discrimination between different lymphocyte subsets. The expression of the activation  
26 markers, CD69 and CD25 on the following lymphocyte subsets was assessed: T lymphocytes (CD3<sup>+</sup>), helper  
27 T cells (Th, CD3<sup>+</sup>CD4<sup>+</sup>), cytotoxic T cells (Tc, CD3<sup>+</sup>CD8<sup>+</sup>), NK cells (CD3<sup>-</sup>CD56<sup>+</sup>), CD8<sup>+</sup> NK cells  
28 (CD8<sup>+</sup>CD56<sup>+</sup>) and CD8<sup>-</sup> NK cells (CD8<sup>-</sup>CD56<sup>+</sup>). Monoclonal antibodies were conjugated to fluorescein  
29 isothiocyanate (FITC), phycoerythrin (PE) or (Cy-5 PE). PBMCs were incubated with fluorescently-labeled  
30 monoclonal antibodies (all from BD Biosciences, Oxford, UK) for 30 min at 4°C in the dark and washed by  
31 Cell Wash (BD Biosciences, Oxford, UK) twice before fixing with Cell Fix (BD Biosciences, Oxford, UK).

1 The fixed cells were analyzed on a Becton Dickinson FACSCalibur flow cytometer (BD Biosciences,  
2 Oxford, UK) within 24 h. The lymphocytes were gated and fluorescence data for 10,000 events were  
3 collected and analyzed by Flowjo 7.6. Results of phenotypes were expressed as the percentage of the subsets  
4 or within the cell group specified. Activation was determined as both the percentage of CD69 or CD25  
5 positive cells in specific cell subsets and mean fluorescence intensity (MFI) for CD69<sup>+</sup> or CD25<sup>+</sup> cells within  
6 a particular cell subset.

#### 7 **Cytokine analysis in cell culture supernatants**

8 The production of IL-1 $\beta$ , IL-6, IL-8, IL-10, IL-12 p70, IL-17A, IFN- $\gamma$ , TNF- $\alpha$ , MCP-1, GM-CSF, MIP-1 $\alpha$ ,  
9 MIP-1 $\beta$  and RANTES was measured using Cytometric Bead Array (CBA) multiplex kits (BD Biosciences,  
10 Oxford, UK) by flow cytometry according to the manufacturer's instructions. BDTM CBA analysis software  
11 (BD Biosciences, Oxford, UK) was used to perform the data analysis.

#### 12 **T cell proliferation**

13 T cell proliferation was measured by the Cell Trace CFSE Cell Proliferation Kit (Invitrogen Ltd, Paisley,  
14 UK). Briefly, PBMC cell suspensions at 1 $\times$ 10<sup>6</sup> cells/mL were incubated with CFSE (final concentration 0.01  
15 mM) at 37 °C, 5 % CO<sub>2</sub> for 10 min and then staining was quenched by ice cold medium and the sample  
16 incubated on ice for 5 min. After washing with RPMI medium containing 10 % autologous plasma, the cells  
17 were resuspended in the same medium and incubated in triplicate with either medium only (control), or with  
18 Con A at final concentrations of 15  $\mu$ g/mL and 7.5  $\mu$ g/mL at 37 °C, 5 % CO<sub>2</sub> for 4 days. The data were  
19 collected by flow cytometry and analyzed using FlowJo 7.6 software.

20 Data are presented as mean and standard error (SE). All data were analyzed using SPSS version 17.0.  
21 Significant differences between the probiotic and placebo periods and between baseline and end of  
22 intervention were evaluated by paired t-test. The sequence effect was tested by indication of treatment\*period  
23 interaction using two way ANOVA and no treatment\*period interaction was observed. The carry over effect  
24 of each treatment was evaluated by comparison of pre-treatment and post wash-out. In one case there was a  
25 carry over effect of the Yakult treatment (% monocytes engaged in phagocytosis), and in this case, only the  
26 first period was analyzed. Bonferroni multiple testing corrections were performed where applicable. The  
27 adjusted significant *P* value was calculated by the chosen level of significance *P* value (0.05) divided by the  
28 appropriate number of tests. Correlations between two normally distributed variables were analyzed by using  
29 Pearson's correlation coefficients.

#### 30 **Results**



1 All volunteers completed the study. There was 100 % compliance with the dietary intervention. The  
2 effects of the different interventions (probiotic or placebo) are detailed below.

### 3 **Effects on blood lipids, inflammatory markers, complement and WBC count**

4 There were no significant effects of probiotic on total cholesterol, triacylglycerol, glucose, CRP or C5a  
5 (data not shown). WBC count was significantly increased from  $4.09 \times 10^9 /L$  to  $4.54 \times 10^9 /L$  after the  
6 placebo treatment ( $P<0.05$ ), but was not significantly different from that during the LcS period.

### 7 **Effects on salivary sIgA**

8 Both LcS and placebo tended to increase salivary sIgA concentrations, but this did not reach statistical  
9 significance (data not shown). The probiotic had no effect on salivary sIgA in volunteers 65 years old or  
10 younger ( $n=18$ ), but there was a borderline increase in salivary sIgA ( $P=0.076$ ) in volunteers over 65y (data  
11 not shown) ( $n=12$ ).

### 12 **Effects on phagocytosis**

13 As there was a carry-over effect of Yakult treatment on the percentage of monocytes engaged in  
14 phagocytosis ( $P=0.000$ ), only the first period of the two treatments was analyzed. There was no effect of  
15 placebo on phagocytosis compared with baseline. LcS significantly increased the percentage of monocytes  
16 engaged in phagocytosis ( $P=0.000$ ) and decreased MFI in granulocytes ( $P=0.002$ ) compared with baseline  
17 (Table 1); however, there was no significant difference between the two treatments.

### 18 **Effects on NK cell activity**

19 NK cell activity was significantly increased after intervention with LcS at an E/T ratio of 100 ( $P=0.008$ ),  
20 and almost reached significance for the E/T ratio of 50 ( $P=0.057$ ) compared to baseline (Fig. 1 a). There was  
21 no effect of the placebo treatment on NK cell activity compared to baseline. Despite the increase in NK cell  
22 activity during the LcS intervention period, there were no significant differences between probiotic and  
23 placebo periods at the end of intervention. Similarly, when NK cell activity was expressed on a per cell basis  
24 (divided by NK cell percentage in lymphocytes), LcS consumption was associated with significant increase  
25 in NK cell activity relative to baseline (Fig. 1 b), but this was not significantly different from the placebo  
26 period. When gender was considered, the probiotic was shown to significantly increase NK activity  
27 compared with baseline in females ( $n=18$ ) ( $P<0.05$ ) but not in males ( $n=12$ ) (Fig. 1 c). It should be noted,  
28 however, that NK cell activity at the beginning of the study was significantly higher in males (19.8 %) than  
29 in females (11.2 %) (Fig. 1 d).

30 Correlation between NK cell activity and NK cell proportion and expression of activation markers on  
31 different subsets was analyzed. NK cell activity showed strong correlation with the proportion of NK cells in

1 the lymphocyte population ( $P<0.001$ ) and CD69 expression (both % and MFI) in the CD8<sup>+</sup>NK cells  
2 stimulated by ConA (both  $P<0.01$ ) (data not shown).

### 3 **Phenotypic analysis of lymphocytes**

4 A summary of lymphocyte phenotypes is shown in Table 2. There were no significant changes in  
5 lymphocyte phenotypes after probiotic supplement.

### 6 **Effects on lymphocyte activation**

7 The expression of two activation markers, CD69 and CD25, on specific lymphocyte subsets was assessed  
8 in both non-stimulated and Con A-stimulated cultures. LcS had no effect on CD69 expression in both of the  
9 resting (non-stimulated) (data not shown) and ConA-stimulated cells (Table 3) of all subgroups in  
10 comparison to placebo. Probiotic consumption was associated with significantly reduction of the MFI for  
11 CD25 expression by resting T cells ( $P=0.003$ ) relative to that during the period of placebo consumption  
12 (Table 4). There is no effect of LcS intake on CD25 expression on ConA-stimulated T cell subsets (Table 4).

### 13 **Effects on cytokine production**

14 The levels of a wide range of cytokines and chemokines were measured in supernatants from LPS-  
15 stimulated PBMC cultures. There was a tendency for IL-10 production to be reduced by the placebo  
16 treatment and increased by LcS, but this did not reach statistical significance (Table 5). Even though the  
17 baseline level of IL-10 in probiotic treatment was lower than that in placebo treatment, there was no  
18 significant difference in the basal values of IL-10 of both treatments ( $P=0.063$ ). The ratio of IL-10/IL-12 was  
19 marginally increased during the LcS period compared with the placebo period ( $P=0.009$ ). (Table 5),

### 20 **Effects on T cell proliferation**

21 Lymphocyte proliferation is expressed as Division Index and % Division. Division Index is the average  
22 number of cell divisions of responding cells, whereas % Divided is the percentage of the cells of the original  
23 sample which divided. There was no significant difference in either parameter between the probiotic and the  
24 placebo periods (data not shown).

### 25 **Discussion**

26 Some components of the immune response, including phagocytosis, NK cell activity and mucosal  
27 immunoglobulin A production (especially in children), have been shown to be improved by certain probiotic  
28 bacterial strains, while other components, including lymphocyte proliferation, the production of cytokines  
29 and production of antibodies other than immunoglobulin A, appear to be less sensitive to probiotic  
30 modulation [16]. The current human study has shown that LcS consumption was associated with an increase  
31 in NK cell activity and monocyte phagocytosis, reduced MFI of CD25 expression on resting T cells and a

1 trend towards an increased ratio of IL-10 to IL-12. There was no effect of LcS on T cell proliferation,  
2 phagocytosis, serum parameters, salivary sIgA or WBC count.

3 Immunoglobulin A (IgA) secretion in saliva decreases with age and may be related to increased  
4 susceptibility of older people to respiratory infections [17]. Studies are inconsistent with regard to the  
5 influence of probiotics on sIgA [18-20]. The current study showed no effect of LcS on salivary sIgA  
6 secretion, but there was a marginal increase in total salivary sIgA secretion in volunteers over 65 y. Since the  
7 number of subjects over 65y in the current study was rather small (n=12), this marginal effect remains to be  
8 confirmed.

9 NK cells are critical for the removal of intracellular pathogens and also possess vital tumoricidal activities,  
10 but their activity declines with ageing [21], even though numbers of NK cells in the circulation increase with  
11 age [22]. Thus, NK cell activity is impaired when considered on a per-cell basis. NK cell activity has been  
12 demonstrated to be enhanced by the majority of probiotic strains studied in healthy adults [6-7,18] and in  
13 older subjects [23-24], although a few studies report no effect [18,25]. In the current study, LcS significantly  
14 increased NK cell activity both overall, and on a per-cell basis. The ability of LcS to promote NK cell  
15 activity has also been reported in other animal/human studies [26-28]. In addition, LcS consumption was  
16 shown to reduce the recurrence of superficial bladder cancer [29], prevent atypia of colorectal tumors in a  
17 randomized trial [30], and reduce the risk of bladder cancer [31].

18 The current study showed that NK cell activity was higher in males than in females, which has been  
19 reported elsewhere [32]. It also demonstrated that LcS consumption had a greater effect on female than on  
20 male volunteers, and this effect might relate to the initially lower NK cell activity in females. This is  
21 supported by evidence that LcS enhanced NK cell activity in healthy younger subjects with relatively low  
22 NK cell [33], maintained NK activity in healthy older subjects [27] and restored NK cell activity in habitual  
23 smokers who had low NK activity [12]. **It has thus been suggested that LcS does not necessarily enhance**  
24 **immune function above ‘normal’ levels in healthy individuals, but rather modulates it back to normal levels**  
25 **in situations where immunity is impaired, and thus plays a role in homeostasis. However, this is contradicted**  
26 **by a study demonstrating no effect of LcS on NK cell activity in healthy subjects specifically selected for**  
27 **reduced NK cell activity [34].**

28 Phagocytosis is decreased during ageing [35]. Several studies have demonstrated that various probiotic  
29 strains promote phagocytic activity in both healthy adults [7,19,18] and elderly subjects [24,36] and one  
30 study reported that LcS restored phagocytic capacity back to normal in patients with alcoholic cirrhosis,  
31 while having no effect in healthy controls [37]. However, some studies report no effect on phagocytosis in

1 colon cancer patients [38], healthy adults [39] and in-patients [40]. The current study showed that LcS  
2 consumption increased the percentage of monocytes engaged in phagocytic activity, but decreased  
3 granulocyte phagocytosis on a per cell basis. Therefore, the net effect of LcS on phagocytic capacity is not  
4 clear.

5 It is reported that age-related changes in human blood lymphocyte subpopulations include an increase in  
6 numbers and/or proportion of NK cells and CD8<sup>+</sup> T cells, but a decrease in T cells, CD4<sup>+</sup> T cells, B cells and  
7 the ratio of CD4<sup>+</sup>/CD8<sup>+</sup> [41-43]. These changes in the T cell profile with age may result from increased  
8 susceptibility to apoptosis of T helper cells and greater resistance to apoptosis of cytotoxic T cells [44]. A  
9 combination of high CD8<sup>+</sup> and low CD4<sup>+</sup> and poor T-cell proliferation in PBMCs was associated with higher  
10 2-year mortality in a sample of very old Swedish individuals [45]. The data regarding the effect of probiotics  
11 on lymphocyte phenotypes are inconsistent. For example, an intervention study [25] with 122 healthy  
12 subjects (18-67y) demonstrated that a mixture of three probiotic strains significantly increased the numbers  
13 of Tc cells, but had no effect on other lymphocyte subsets. Other studies demonstrated a significant increase  
14 in CD3<sup>+</sup>, CD25<sup>+</sup> and CD56<sup>+</sup> cells, but no changes in CD4<sup>+</sup>, CD8<sup>+</sup>, CD19<sup>+</sup> or HLA-DR<sup>+</sup> cells after *B. lactis*  
15 HN019 intake in older volunteers [3] and an increase in CD4<sup>+</sup> T cell population, but no effect on other  
16 phenotypes by consumption of *L. paracasei* [46]. This increase in CD4<sup>+</sup> cells after probiotic consumption  
17 was also observed in mice fed *L. fermentum* PL9005 [47]. The current study showed that intervention with  
18 LcS had no effect on the proportion of Th or Tc cells. Consistent with this, there was no effect of LcS on the  
19 proportions of CD4<sup>+</sup> and CD8<sup>+</sup> cells in a small uncontrolled human study [27]. In addition, The current study  
20 demonstrated a decrease in CD25 expression by resting T cells and Th cells following LcS consumption.  
21 There is little comparative data, but similar results have been reported for *L. rhamnosus* GG [48].

22 The reported effects of probiotics on cytokine production are complex and suggest strain-specific  
23 differences [2,27]. A range of cytokines and chemokines were examined in the current study, but there were  
24 no significant changes in cytokine and chemokine production by LcS. However, the ratio of IL-10 to IL-12  
25 was tended to increase in association with LcS consumption, which indicates a shift towards a more anti-  
26 inflammatory profile. This could be beneficial to older people, given the increase in circulating inflammatory  
27 mediators with ageing as a result of lifelong infectious burden [42]. Other human studies with LcS showed  
28 no changes in stimulated cytokine production of IL-1 $\beta$ , IL-2, IL-4, IL-6, IL-8, IL-10, IFN- $\gamma$ , TNF- $\alpha$  or MCP-1  
29 in athletes [14], but significant reduction of allergen-induced IL-5, IL-6 and IFN-production compared with a  
30 placebo in volunteers with seasonal allergic rhinitis [13].

1       There are some limitations associated with the single blind nature of the study, but this was unavoidable  
2 due to the nature and packaging of the products. The most appropriate placebo would ideally be a milk  
3 product identical to Yakult Light, but with no bacteria. This placebo has been employed in some studies [49-  
4 50], but was unavailable to us. We selected UHT skimmed milk as the next best option, since its nutrient  
5 content very closely matches that of Yakult Light and it has been used as a placebo in several other trials  
6 [27,10]. A further limitation was that we did not specifically select subjects who were immunocompromised.  
7 Each of the aspects of immunity evaluated in this study is subject to modulation by ageing, although because  
8 of the enormous variation amongst healthy subjects, defining thresholds for compromised immune function  
9 is very difficult. The hypothesis of this study was that LcS would at least partially reverse some of the decline  
10 in immune parameters caused by ageing. Although it cannot be ascertained whether the subjects in the  
11 current study were immunocompromised. Immunosenescence is observed even in healthy ageing and the  
12 purpose of this study was simply to investigate an older group (which was expected to have some degree of  
13 immunosenescence). It could be argued that the results from this study could also be applied to younger  
14 subjects and to those who are not necessarily immunocompromised. Finally, a limitation of all studies  
15 employing immune biomarkers in the absence of clinical outcomes is that it is difficult to interpret the  
16 biological significance of minor immunomodulatory effects. There is a tendency to assume that because low  
17 NK activity is associated with higher risk of infection and cancer, reverting this will be beneficial. To date,  
18 there is little evidence to support this and more clinical data is required.

19       In conclusion, the probiotic LcS may promote innate immunity by increasing NK cell activity and may  
20 improve inflammatory status by increasing the IL-10/IL-12 ratio in older people. Further studies are required  
21 to evaluate the immunomodulatory effects of LcS on the incidence and severity of infection, and the  
22 mechanisms by which LcS modulates immune function.

### 23 **Acknowledgements**

24       All authors contributed to the study design, analysis of the data and preparation of the manuscript. All  
25 authors read and approved the final manuscript.

### 26 **Conflict of interest statement**

27       This research was sponsored by a Dorothy Hodgkin Postgraduate Award and Yakult UK Limited. Dr.  
28 Thomas is an employee of Yakult UK Limited.

### 29 **References**

30 1. Weiskopf D, Weinberger B, Grubeck-Loebenstien B (2009) The aging of the immune system. *Transplant*  
31 *Int* 22 (11):1041-1050. doi:10.1111/j.1432-2277.2009.00927.x

- 1 2. Bunout D, Barrera G, Hirsch S, Gattas V, de la Maza MP, Haschke F, Steenhout P, Klassen P, Hager C,  
2 Avendano M, Petermann M, Munoz C (2004) Effects of a nutritional supplement on the immune response  
3 and cytokine production in free-living Chilean elderly. *J Parenter Enter Nutr* 28 (5):348-354
- 4 3. Gill HS, Rutherford KJ, Cross ML, Gopal PK (2001) Enhancement of immunity in the elderly by dietary  
5 supplementation with the probiotic *Bifidobacterium lactis* HN019. *Am J Clin Nutr* 74 (6):833-839
- 6 4. O'Toole PW, Claesson MJ (2010) Gut microbiota: Changes throughout the lifespan from infancy to  
7 elderly. *Int Dairy J* 20 (4):281-291. doi:10.1016/j.idairyj.2009.11.010
- 8 5. Woodmansey EJ (2007) Intestinal bacteria and ageing. *J Appl Microbiol* 102 (5):1178-1186. doi:JAM3400  
9 [pii] 10.1111/j.1365-2672.2007.03400.x [doi]
- 10 6. Zanini K, Marzotto M, Castellazzi A, Borsari A, Dellaglio F, Torriani S (2007) The effects of fermented  
11 milks with simple and complex probiotic mixtures on the intestinal microbiota and immune response of  
12 healthy adults and children. *Int Dairy J* 17 (11):1332-1343. doi:10.1016/j.idairyj.2007.01.017
- 13 7. Klein A, Friedrich U, Vogelsang H, Jahreis G (2008) *Lactobacillus acidophilus* 74-2 and *Bifidobacterium*  
14 *animalis* subsp lactis DGCC 420 modulate unspecific cellular immune response in healthy adults. *Eur J*  
15 *Clin Nutr* 62 (5):584-593. doi:10.1038/sj.ejcn.1602761
- 16 8. Wichers H (2009) Immunomodulation by food: promising concept for mitigating allergic disease? *Anal*  
17 *Bioanal Chem* 395 (1):37-45. doi:10.1007/s00216-009-2838-1
- 18 9. Tuohy KM, Pinart-Gilberga M, Jones M, Hoyles L, McCartney AL, Gibson GR (2007) Survivability of a  
19 probiotic *Lactobacillus casei* in the gastrointestinal tract of healthy human volunteers and its impact on  
20 the faecal microflora. *J Appl Microbiol* 102 (4):1026-1032. doi:JAM3154 [pii] 10.1111/j.1365-  
21 2672.2006.03154.x [doi]
- 22 10. Spanhaak S, Havenaar R, Schaafsma G (1998) The effect of consumption of milk fermented by  
23 *Lactobacillus casei* strain Shirota on the intestinal microflora and immune parameters in humans. *Eur J*  
24 *Clin Nutr* 52 (12):899-907
- 25 11. Sakai T, Makino H, Ishikawa E, Oishi K, Kushiro A (2011) Fermented milk containing *Lactobacillus*  
26 *casei* strain Shirota reduces incidence of hard or lumpy stools in healthy population. *Int J Food Sci Nutr*  
27 Epub ahead of print
- 28 12. Morimoto K, Takeshita T, Nanno M, Tokudome S, Nakayama K (2005) Modulation of natural killer cell  
29 activity by supplementation of fermented milk containing *Lactobacillus casei* in habitual smokers. *Prev*  
30 *Med* 40 (5):589-594

- 1 13. Ivory K, Chambers SJ, Pin C, Prieto E, Arques JL, Nicoletti C (2008) Oral delivery of *Lactobacillus*  
2 *casei* Shirota modifies allergen-induced immune responses in allergic rhinitis. Clin Exp Allergy 38  
3 (8):1282-1289. doi:10.1111/j.1365-2222.2008.03025.x
- 4 14. Gleeson M, Bishop NC, Oliveira M, Tauler P (2011) Daily Probiotic's (*Lactobacillus casei* Shirota)  
5 Reduction of Infection Incidence in Athletes. Int J Sport Nutr Exerc Metab 21 (1):55-64
- 6 15. Kang M, Ragan BG, Park JH (2008) Issues in outcomes research: An overview of randomization  
7 techniques for clinical trials. J Athl Train 43 (2):215-221
- 8 16. Lomax AR, Calder PC (2009) Probiotics, immune function, infection and inflammation: a review of the  
9 evidence from studies conducted in humans. Curr Pharm Des 15 (13):1428-1518
- 10 17. Kotani Y, Shinkai S, Okamatsu H, Toba M, Ogawa K, Yoshida H, Fukaya T, Fujiwara Y, Chaves PH,  
11 Kakumoto K, Kohda N (2010) Oral intake of *Lactobacillus pentosus* strain b240 accelerates salivary  
12 immunoglobulin A secretion in the elderly: A randomized, placebo-controlled, double-blind trial. Immun  
13 Ageing 7:11
- 14 18. Berman SH, Eichelsdoerfer P, Yim D, Elmer GW, Wenner CA (2006) Daily ingestion of a nutritional  
15 probiotic supplement enhances innate immune function in healthy adults. Nutrition Research 26 (9):454-  
16 459. doi:10.1016/j.nutres.2006.08.002
- 17 19. Olivares M, Diaz-Ropero MP, Gomez N, Lara-Villoslada F, Sierra S, Maldonado JA, Martin R,  
18 Rodriguez JM, Xaus J (2006) The consumption of two new probiotic strains, *Lactobacillus gasseri* CECT  
19 5714 and *Lactobacillus coryniformis* CECT 5711, boosts the immune system of healthy humans. Int  
20 Microbiol 9 (1):47-52
- 21 20. Christensen HR, Larsen CN, Kaestel P, Rosholm LB, Sternberg C, Michaelsen KF, Frokiaer H (2006)  
22 Immunomodulating potential of supplementation with probiotics: a dose-response study in healthy young  
23 adults. FEMS Immunol Med Microbiol 47 (3):380-390. doi:10.1111/j.1574-695X.2006.00109.x
- 24 21. Plackett TP, Boehmer ED, Faunce DE, Kovacs EJ (2004) Aging and innate immune cells. J Leukocyte  
25 Biol 76 (2):291-299. doi:10.1189/jlb.1103592
- 26 22. Solana R, Alonso MC, Pena J (1999) Natural killer cells in healthy aging. Exp Gerontol 34 (3):435-443
- 27 23. Elmadfa I, Klein P, Meyer AL (2010) Immune-stimulating effects of lactic acid bacteria *in vivo* and *in*  
28 *vitro*. Proc Nutr Soc 69 (3):416-420. doi:10.1017/s0029665110001710
- 29 24. Gill HS, Rutherford KJ (2001) Probiotic supplementation to enhance natural immunity in the elderly:  
30 effects of a newly characterized immunostimulatory strain *Lactobacillus rhamnosus* HN001 (DR20  
31 (TM)) on leucocyte phagocytosis. Nutrition Research 21 (1-2):183-189

- 1 25. de Vrese M, Winkler P, Rautenberg P, Harder T, Noah C, Laue C, Ott S, Hampe J, Schreiber S, Heller K,  
2 Schrezenmeir J (2005) Effect of *Lactobacillus gasseri* PA 16/8, *Bifidobacterium longum* SP 07/3, *B-*  
3 *bifidum* MF 20/5 on common cold episodes: A double blind, randomized, controlled trial. Clin Nutr 24  
4 (4):481-491. doi:10.1016/j.clnu.2005.02.006
- 5 26. Hori T, Kiyoshima J, Yasui H (2003) Effect of an oral administration of *Lactobacillus casei* strain Shirota  
6 on the natural killer activity of blood mononuclear cells in aged mice. Biosci Biotechnol Biochem 67  
7 (2):420-422
- 8 27. Takeda K, Okumura K (2007) Effects of a fermented milk drink containing *Lactobacillus casei* strain  
9 shirota on the human NK-cell activity. J Nutr 137 (3):791S-793S
- 10 28. Matsuzaki T, Saito M, Usuku K, Nose H, Izumo S, Arimura K, Osame M (2005) A prospective  
11 uncontrolled trial of fermented milk drink containing viable *Lactobacillus casei* strain Shirota in the  
12 treatment of HTLV-1 associated myelopathy/tropical spastic paraparesis. J Neurol Sci 237 (1-2):75-81.  
13 doi:10.1016/j.jns.2005.05.011
- 14 29. Aso Y, Akaza H, Kotake T, Tsukamoto T, Imai K, Naito S (1995) Preventive effect of a *lactobacillus*  
15 *casei* preparation on the recurrence of superficial bladder-cancer in a double-blind trial Eur Urol 27  
16 (2):104-109
- 17 30. Ishikawa H, Akedo I, Otani T, Suzuki T, Nakamura T, Takeyama I, Ishiguro S, Miyaoka E, Sobue T,  
18 Kakizoe T (2005) Randomized trial of dietary fiber and *Lactobacillus casei* administration for prevention  
19 of colorectal tumors. Int J Cancer 116 (5):762-767. doi:10.1022/ijc.21115
- 20 31. Ohashi Y, Nakai S, Tsukamoto T, Masumori N, Akaza H, Miyana N, Kitamura T, Kawabe K, Kotake  
21 T, Kuroda M, Naito S, Koga H, Saito Y, Nomata K, Kitagawa M, Aso Y (2002) Habitual intake of lactic  
22 acid bacteria and risk reduction of bladder cancer. Urol Int 68 (4):273-280
- 23 32. Oshimi K, Gonda N, Sumiya M, Kano S (1980) Effects of corticosteroids on natural-killer cell activity in  
24 systemic lupus-erythematosus. Clin Exp Immunol 40 (1):83-88
- 25 33. Nagao F, Nakayama M, Muto T, Okumura K (2000) Effects of a fermented milk drink containing  
26 *Lactobacillus casei* strain Shirota on the immune system in healthy human subjects. Biosci Biotechnol  
27 Biochem 64 (12):2706-2708
- 28 34. Seifert S, Bub A, Franz C, Watzl B (2011) Probiotic *Lactobacillus casei* Shirota supplementation does  
29 not modulate immunity in healthy men with reduced natural killer cell activity. J Nutr 141 (5)
- 30 35. Aw D, Silva AB, Palmer DB (2007) Immunosenescence: emerging challenges for an ageing population.  
31 Immunology 120 (4):435-446. doi:10.1111/j.1365-2567.2007.02555.x



- 1 36. Arunachalam K GH, Chandra RK. (2000) Enhancement of natural immune function by dietary  
2 consumption of *Bifidobacterium lactis* HN019. Eur J Clin Nutr 54:263-267
- 3 37. Stadlbauer V, Mookerjee R, Wright G, Hodges S, Jalan R (2008) Restoration of the defective innate  
4 immune system following treatment with the probiotic *Lactobacillus casei* Shirota in patients with  
5 alcoholic cirrhosis: A proof of concept study. Wien Klin Wochenschr 120 (15-16):A44-A44
- 6 38. Roller M, Clune Y, Collins K, Rechkemmer G, Watzl B (2007) Consumption of prebiotic inulin enriched  
7 with oligofructose in combination with the probiotics *Lactobacillus rhamnosus* and *Bifidobacterium*  
8 *lactis* has minor effects on selected immune parameters in polypectomised and colon cancer patients. Br J  
9 Nutr 97 (4):676-684. doi:10.1017/s0007114507450292
- 10 39. Olivares M, Diaz-Ropero MP, Sierra S, Lara-Villoslada F, Fonolla J, Navas M, Rodriguez JM, Xaus J  
11 (2007) Oral intake of *Lactobacillus fermentum* CECT5716 enhances the effects of influenza vaccination.  
12 Nutrition 23 (3):254-260. doi:10.1016/j.nut.2007.01.004
- 13 40. Fukushima Y, Miyaguchi S, Yamano T, Kaburagi T, Iino H, Ushida K, Sato K (2007) Improvement of  
14 nutritional status and incidence of infection in hospitalised, enterally fed elderly by feeding of fermented  
15 milk containing probiotic *Lactobacillus johnsonii* La1 (NCC533). Br J Nutr 98 (5):969-977.  
16 doi:10.1017/s0007114507764723
- 17 41. Jiao Y, Qiu ZF, Xie J, Li DJ, Li TS (2009) Reference ranges and age-related changes of peripheral blood  
18 lymphocyte subsets in Chinese healthy adults. Sci China Ser C-Life Sci 52 (7):643-650.  
19 doi:10.1007/s11427-009-0086-4
- 20 42. Gameiro C, Romao F (2010) Changes in the immune system during menopause and aging. Front Biosci  
21 (Elite Ed) 2:1299-1303
- 22 43. Heaton PR, Blount DG, Devlin P, Koelsch S, Mann SJ, Smith BHE, Stevenson J, Harper EJ (2002)  
23 Assessing age-related changes in peripheral blood leukocyte phenotypes in labrador retriever dogs using  
24 flow cytometry. J Nutr 132 (6):1655S-1657S
- 25 44. Targonski PV, Jacobson RM, Poland GA (2007) Immunosenescence: Role and measurement in influenza  
26 vaccine response among the elderly. Vaccine 25 (16):3066-3069. doi:10.1016/j.vaccine.2007.01.025
- 27 45. Olsson J, Wikby A, Johansson B, Lofgren S, Nilsson BO, Ferguson FG (2000) Age-related change in  
28 peripheral blood T-lymphocyte subpopulations and cytomegalovirus infection in the very old: the  
29 Swedish longitudinal OCTO immune study. Mech Ageing Dev 121 (1-3):187-201

- 1 46. Jahreis G, Vogelsang H, Kiessling G, Schubert R, Bunte C, Hammes WP (2002) Influence of probiotic  
2 sausage (*Lactobacillus paracasei*) on blood lipids and immunological parameters of healthy volunteers.  
3 Food Res Int 35 (2-3):133-138
- 4 47. Park JH, Lee YH, Moon E, Seok SH, Cho SA, Baek MW, Lee HY, Kim DJ (2005) Immunoenhancing  
5 effects of a new probiotic strain, *Lactobacillus fermentum* PL9005. J Food Prot 68 (3):571-576
- 6 48. Braat H, van den Brande J, van Tol E, Hommes D, Peppelenbosch M, van Deventer S (2004)  
7 *Lactobacillus rhamnosus* induces peripheral hyporesponsiveness in stimulated CD4(+) T cells via  
8 modulation of dendritic cell function. Am J Clin Nutr 80 (6):1618-1625
- 9 49. Koebnick C, Wagner I, Leitzmann P, Stern U, Zunft HJF (2003) Probiotic beverage containing  
10 *Lactobacillus casei* Shirota improves gastrointestinal symptoms in patients with chronic constipation. Can  
11 J Gastroenterol 17 (11):655-659
- 12 50. De Preter V, VanhoutteT, G H, J S, De Vuyst L, P R, K V (2007) Effects of *Lactobacillus casei* Shirota,  
13 *Bifidobacterium breve*, and oligofructose-enriched inulin on colonic nitrogen-protein metabolism in  
14 healthy humans. Am J Physiol Gastrointest Liver Physiol 292:G358–G368

15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31

1 **Figure legends**

2 **Fig. 1** Effect of probiotic *Lactobacillus casei* Shirota (LcS) consumption on NK cell activity. Data are  
3 mean  $\pm$  SE. (a) specific lysis (%) before and after probiotic (LcS) or placebo supplement. The ratios of  
4 effector/target cells (E/T) were 100:1 and 50:1. (b) Specific lysis on a per cell basis. E/T=100/1. (c) Effect of  
5 LcS supplement on NK cell activity in female (n) =18 and male volunteers (n=12). E/T=100/1. \* $P$ <0.05,  
6 \*\* $P$ <0.01 compared with baseline (before supplement). (d). NK cell activity at the beginning of the study in  
7 females and males. E/T=100/1. \* $P$ <0.05 compared with females.

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

1 **Table 1** Effect of probiotic *Lactobacillus casei* Shirota (LcS) on leucocytic phagocytosis

	Placebo		Yakult	
	Before	After	Before	After
Granu %	95.49 ± 0.90	97.06 ± 0.30	94.09 ± 1.00	92.53 ± 2.43
Mono %	81.03 ± 1.91	84.90 ± 1.15	79.77 ± 1.59	87.50 ± 1.00 #◇
Granu MFI	268.56 ± 18.99	212.13 ± 18.20	277.52 ± 24.84	181.85 ± 16.53 *
Mono MFI	130.17 ± 9.29	99.46 ± 8.26	132.53 ± 8.94	98.05 ± 9.53

2

3 Data are mean ± SE. Abbreviations: Granu-granulocytes, Mono-monocytes, MFI-mean fluorescence  
 4 intensity. The significant level of *P* value is 0.05/4=0.01 after Bonferroni correction. \**P*=0.002, #*P*=0.000  
 5 compared with baseline. ◇ only the first period of the two treatments was analyzed because of the carry over  
 6 effect of Yakult treatment

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

1 **Table 2** Effect of probiotic *Lactobacillus casei* Shirota (LcS) intervention on lymphocyte subpopulations

Group	Placebo					Probiotic (LcS)					P value <sup>a</sup>		
	Before	SE	After	SE	Difference		Before	SE	After	SE		Difference	
					Mean	SE						Mean	SE
T cell %/Lym	75.79	1.02	75.07	1.43	-0.72	0.81	74.26	1.40	74.35	1.23	-0.21	0.86	0.73
Th %/Lym	50.33	1.80	49.77	2.10	-0.56	0.65	49.25	1.94	51.45	2.15	1.15	0.89	0.05
Tc %/Lym	23.23	1.70	23.64	1.88	0.41	0.72	23.69	1.69	21.20*	1.72	-1.77	0.79	0.11
Tc %/T cells	29.5	1.10	28.89	2.65	0.41	0.91	30.14	2.29	27.93*	0.40	-2.21	1.03	0.07
NK %/Lym	13.99	0.98	14.22	1.11	0.23	0.82	15.78	1.19	15.00	1.16	-0.52	0.73	0.45
CD8+NK %/Lym	14.35	1.07	16.06	1.21	1.71	0.93	17.66	1.06	14.77	1.43	-2.54	1.08	0.01
CD8-NK %/Lym	5.02	0.55	4.91	0.51	-0.11	0.25	5.16	0.56	5.32	0.58	0.29	0.20	0.22
CD8+NK %/CD56+	76.38	1.51	77.87	1.47	1.49	1.13	79.50	1.40	74.30	1.84	-5.17	1.60	0.01
CD8-NK %/CD56+	23.21	1.50	21.34	1.42	-1.86	1.08	20.11	1.41	24.56	1.68	4.40	1.39	0.01

2 Data are mean ± SE. <sup>a</sup>paired t-test on the mean change from baseline for the placebo and probiotic

3 periods. Abbreviation; Lym-lymphocytes. The significant P value after Bonferroni correction is

4 0.05/9=0.0056.

5

6

7

8

9

10

11

12

**Table 3** Effect of probiotic *Lactobacillus casei* Shirota (LcS) intervention on expression of CD69 by ConA-stimulated lymphocyte subpopulations

Culture	Cell group	Parameters	Placebo				Probiotic (LcS)				<i>P</i> value <sup>a</sup>				
			Before	SE	After	SE	Difference		Before	SE		After	SE	Difference	
							Mean	SE						Mean	SE
ConA-stimulated	T cells	CD69 %	42.86	1.91	42.48	2.05	-0.37	1.55	38.60	1.77	41.62	2.25	3.02	1.76	0.11
		CD69 MFI	66.66	2.03	67.27	2.72	0.61	2.72	64.95	1.96	70.88	3.25	5.93	2.58	0.12
	Th	CD69 %	49.73	1.99	50.00	1.85	0.27	1.53	43.90	1.88	48.36	2.58	4.46	1.94	0.04
		CD69 MFI	85.79	3.65	85.09	3.85	-0.70	3.96	85.60	2.35	91.62	3.93	6.02	3.59	0.23
	Tc	CD69 %	40.82	2.40	38.97	2.98	-1.85	2.15	40.80	2.31	39.56	2.62	-1.24	1.95	0.84
		CD69 MFI	45.34	1.62	44.12	1.80	-1.22	1.66	44.73	1.30	47.83	2.95	3.10	2.43	0.08

Data are mean ± SE. <sup>a</sup> paired t-test on the mean change from baseline between the placebo and LcS periods. The significant *P* value after Bonferroni correction is

0.05/6=0.0083.

**Table 4** Effect of probiotic *Lactobacillus casei* Shirota (LcS) intervention on expression of CD25 by lymphocyte subpopulations

Cultures	Cell group	Parameters	Placebo				Probiotic (LcS)				P value <sup>a</sup>				
			Before	SE	After	SE	Difference		Before	SE		After	SE	Difference	
							Mean	SE						Mean	SE
Unstimulated	T cells	CD25 %	7.83	0.48	6.63	0.44	-1.19	0.35	8.02	0.45	6.96	0.55	-1.20	0.48	0.99
		CD25 MFI	15.12	0.26	15.99	0.25	0.84	0.23	15.43	0.20	15.11	0.20	-0.22	0.29	0.003
	Th	CD25 %	9.36	0.56	8.91	0.68	-0.40	0.60	10.49	0.68	8.53*	0.53	-2.15	0.76	0.06
		CD25 MFI	15.54	0.30	15.78	0.31	0.27	0.39	16.28	0.49	15.95	0.41	-0.21	0.29	0.41
	Tc	CD25 %	2.92	0.38	2.07	0.31	-0.86	0.32	3.78	0.48	2.69	0.39	-1.14	0.33	0.52
		CD25 MFI	14.48	0.55	14.72	0.37	0.23	0.70	13.48	0.28	13.93	0.38	0.37	0.50	0.87
ConA-stimulated	T cells	CD25 %	40.55	1.85	39.50	2.19	-1.05	1.31	36.82	2.01	39.30	1.95	2.48	1.70	0.09
		CD25 MFI	39.98	1.87	39.84	1.80	-0.14	1.39	38.01	1.93	38.82	1.71	0.80	1.51	0.70
	Th	CD25 %	46.02	2.05	44.92	2.08	-1.10	1.57	41.59	1.99	44.69	2.21	3.10	1.73	0.06
		CD25 MFI	37.92	1.20	35.57	1.49	-2.35	1.66	37.13	0.22	36.87	1.85	-0.26	1.75	0.44
	Tc	CD25 %	37.33	2.46	33.79	3.52	-3.53	1.96	35.15	2.60	33.30	2.81	-1.85	2.38	0.59
		CD25 MFI	55.36	2.95	52.97	3.44	-2.39	2.47	52.80	3.27	50.73	3.31	-2.07	2.86	0.95

Data are mean  $\pm$  SE. <sup>a</sup>paired t-test on the mean change from baseline between the placebo and Yakult periods. The significant *P* value after Bonferroni correction is

0.05/6=0.0083.


**Table 5** Effect of probiotic *Lactobacillus casei* Shirota (LcS) intervention on cytokine/chemokine production by LPS-stimulated PBMC

Cytokine (pg/mL)	Placebo						Probiotic (LcS)						P value <sup>a</sup>
	Before	SE	After	SE	Difference		Before	SE	After	SE	Difference		
					Mean	SE					Mean	SE	
GM-CSF	114.16	15.74	117.94	18.25	3.78	15.06	101.01	16.21	83.93	10.25	-17.08	15.33	0.31
IFN- $\gamma$	33.05	13.89	37.52	9.13	4.47	12.16	87.25	62.04	49.10	19.84	-38.15	43.82	0.24
IL-10	343.42	69.84	314.75	49.08	-28.67	39.62	267.09	64.59	306.27	48.63	39.18	41.06	0.07
IL-12p70	5.06	0.62	5.28	0.62	0.23	0.48	5.50	0.65	5.42	0.55	-0.08	0.54	0.71
IL-17A	1.14	0.35	1.77	0.49	0.63	0.58	1.49	0.44	1.82	0.42	0.32	0.45	0.67
MCP-1	8191.65	1019.59	8049.84	888.52	-141.82	640.07	8584.31	966.53	8340.17	849.95	-244.15	712.60	0.91
RANTES	2907.01	187.04	3413.50	260.09	506.49	268.86	3241.55	224.22	3375.84	299.88	134.28	276.95	0.32
TNF- $\alpha$	426.17	76.63	380.14	60.75	-46.04	68.60	260.38	41.96	313.61	53.01	53.24	52.38	0.24
IL-1 $\beta$	1979.35	205.17	2276.54	207.97	297.20	244.48	2062.33	217.65	2241.73	262.95	179.40	302.89	0.76
IL-6	15220.78	1190.89	15432.74	891.24	211.96	1283.10	15584.70	1281.72	14169.52	944.53	-1415.19	1108.16	0.31
IL-8	66231.30	3866.58	67623.92	3131.52	1392.62	3991.48	68757.59	4117.72	64173.38	3390.92	-4584.21	2886.65	0.28
MIP-1 $\alpha$	5599.89	440.81	5573.80	334.21	-26.08	456.52	5667.34	475.56	5390.90	364.95	-276.44	399.72	0.69
MIP-1 $\beta$	18870.50	1788.78	18807.90	1555.70	-62.60	1838.64	18263.86	1214.79	17930.37	1549.01	-333.49	1295.09	0.89
IL-10/IL-12	71.49	16.11	61.29	16.24	-10.20	9.24	46.02	6.95	71.63	14.80	26.74	13.70	0.009
TNF- $\alpha$ /IL-10	2.27	0.63	2.03	0.47	-0.24	0.40	1.68	0.46	1.46	0.35	-0.22	0.28	0.93
IL-1 $\beta$ /IL-12	463.01	63.30	593.74	118.85	130.74	102.54	478.08	71.88	581.05	110.39	103.13	113.95	0.97

Data are mean  $\pm$  SE. <sup>a</sup>paired t-test on the mean change from baseline between the placebo and probiotic periods. The significant *P* value after Bonferroni correction is

0.05/13=0.0039.





**Fig. 1** Effect of probiotic *Lactobacillus casei* Shirota (LcS) consumption on NK cell activity